Navigation Links
AcelRx Pharmaceuticals Receives Fourth and Fifth U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
Date:8/29/2012

livery and the inherent potential for programming and delivery errors associated with the complexity of infusion pumps.  AcelRx has two additional product candidates which have completed Phase 2 clinical development: ARX-02 for the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician's office.   AcelRx plans to initiate a Phase 2 study, pending protocol approval, for a fourth product candidate, ARX-04, a sufentanil formulation for the treatment of moderate-to-severe acute pain, funded through a grant from USAMRMC.  For additional information about AcelRx's clinical programs please visit www.acelrx.com.

Forward Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to AcelRx Pharmaceuticals' patent portfolio, including the useful life of its U.S. patents and the European patent, the continued expansion of its patent protection, market exclusivity, its ability to protect its proprietary technology, the scope of patent protection, and issued and planned or anticipated future clinical development of AcelRx Pharmaceuticals' product candidates, including the execution of the Phase 3 clinical studies for ARX-01,  the initiation of Phase 2 clinical trial for ARX-04, and the therapeutic potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking statements are based on AcelRx Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to: the success, cost and timing of AcelRx Pharmaceuticals' product development activities and c
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AcelRx Pharmaceuticals Reports First Quarter 2012 Financial Results
2. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
3. AcelRx Pharmaceuticals, Inc. to Webcast, Live, at RetailInvestorConferences.com on July 12th
4. AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
5. AcelRx Pharmaceuticals Receives Two Additional U.S. Patents for Small-Volume Oral Transmucosal Dosage Forms
6. AcelRx Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call and Webcast on August 9, 2012
7. AcelRx Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Healthcare Conference
8. AcelRx Pharmaceuticals Reports Second Quarter 2012 Financial Results
9. AcelRx Pharmaceuticals to Present at Three Upcoming Investor Conferences
10. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
11. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... International Isotopes Inc. (OTCQB: INIS) (the "Company") ... 31, 2014.  The Company reports a 10% increase in ... cash flow for the year ended December 31, 2014. ... approximately $7.5 million compared to approximately $6.8 million in ... the exception of the radiological services segment, our three ...
(Date:4/1/2015)... , April 1, 2015 ... Report on Global Azithromycin Industry and 2015 ... Industry reports added to Pharmaceutical category in ... the report introduces Azithromycin basic information, including ... overview, policy analysis, and news analysis, etc. ...
(Date:4/1/2015)... 1, 2015 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug ... enrolled in its Glucose Clamp Study. The study will ... Center at San Antonio and ... of Professor Ralph DeFronzo . The ...
Breaking Medicine Technology:International Isotopes Inc. Announces 2014 Year End Financial Results 2International Isotopes Inc. Announces 2014 Year End Financial Results 3International Isotopes Inc. Announces 2014 Year End Financial Results 4International Isotopes Inc. Announces 2014 Year End Financial Results 5International Isotopes Inc. Announces 2014 Year End Financial Results 6International Isotopes Inc. Announces 2014 Year End Financial Results 7Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 2Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 3Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 4Azithromycin Market & Polypeptide Drug Industry - Global Research Reports 5Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 2Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin 3
... Dr. Lowell S. Kabnick, MD, RPhS, FACS, FACPh, Director ... in the field of vascular surgery, is once again leading ... country to use the new VenaCure® 1470nm laser to treat ... compared with other lasers resulting in effective vein closure. ...
... Enzymatics , Inc. announced today that the company, ... forecasting triple the revenue in 2011 over 2010 figures. ... facility in Beverly, Massachusetts.  The move is one of ... firm that supplies biological reagents as well as bio-processing ...
Cached Medicine Technology:Dr. Lowell S. Kabnick First to Use New VenaCure® 1470nm Laser 2Enzymatics Reports Latest Growth Figures; Confirms Massachusetts' Emerging Role as Leading Bio-manufacturing Center 2
(Date:4/1/2015)... EAGAN, Minn. (April 1, 2015) —Blue Cross and ... (Blue Cross) today announced audited financial results for 2014. ... of $61.5 million, reflecting positive investment portfolio performance that ... operating loss of $8.2 million on full-year revenues of ... of one percent (0.1%). , Blue Cross reported ...
(Date:4/1/2015)... SCI Solutions , the health ... announced that CEO Joel French will be a featured ... Exhibition in Chicago, April 12-16, 2015. French will ... Care Coordination Strategies ” with Northeast Georgia Health System ... More than 38,000 healthcare industry professionals are expected at ...
(Date:4/1/2015)... Dr. Daniel C. Stewart will ... discuss the benefits of the LANAP® treatment over traditional ... disease. People who live in Howard County, and surrounding ... now visit Dr. Stewart, a Maryland dentist, for a ... LANAP® protocol, which is a laser gum surgery procedure, ...
(Date:4/1/2015)... Dr Roz Kamani, a Vancouver medical aesthetic ... her patients an opportunity to learn more about the ... Days”, which is an exclusive VIP event conducted three ... Care Clinic. It is attended by Dr Roz Kamani’s ... products and services that are on offer. , ...
(Date:4/1/2015)... Parents of teenaged and adolescent children might want ... post discusses Teen Violence Related to Substance Abuse. As ... Awareness Month, the substance abuse treatment center has issued ... identify if there may be problems with their kids ... alcohol. , “People learn how to establish healthy relationships ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 2Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 3Health News:SCI Solutions CEO Joel French and Northeast Georgia Health System to Present at HIMSS15 4Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Dr Roz Kamani Now Offers Patients The Opportunity to Learn About Latest Products and Services 2Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2
... traditional Chinese medicine (TCM) is one of the ... of gastrointestinal microflora are broken, which plays many ... of the host. Therefore, more clinical interests are ... intestinal disease and the consequent treatment, especially in ...
... are top at boozing! In the current edition of ... 106 (19): 323𔃆), Martin Stolle et al. of the ... in Hamburg report that the main change has been ... their article, the authors present motivating short-term interventions to ...
... clinically by a simple method as a preoperative renal ... filtration rate (GFR). Recently, an equation for estimated GFR ... has been accepted as equal to measured GFR in ... studies regarding the reliability of eGFR as a preoperative ...
... that you can personalize.PITTSBURGH, May 22 ... of Computerized Maintenance Management Systems (CMMS) for the healthcare ... personalize.This new product offering is a CMMS application that ... business problems. Users can create their own screen layouts ...
... Third Annual Gout Awareness Day (May 22) NEW YORK, ... announced today that new survey results reveal alarming gaps in ... form of arthritis that affects three to five million Americans. ... of adults admitted to being "not at all knowledgeable" about ...
... Health Group Inc. ("AIM" or the "Company") (TSXV - ... that its income for the three months ended March ... loss of $32,194 in the same period in 2008. ... from $248,810, on a quarter-over-quarter basis. This is the ...
Cached Medicine News:Health News:An efficient approach to monitor gastrointestinal microflora changes 2Health News:A first choice of renal function tests in hepatectomy patients 2Health News:Four Rivers Software System Launches TMS OnSite Professional 2Health News:The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout 2Health News:The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout 3Health News:AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR 2Health News:AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR 3Health News:AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: